Phase 2 IgA Nephropathy (IgAN) Clinical Trials
5 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–5 of 5 trials
Recruiting
Phase 2
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
IgA Nephropathy (IgAN)IgANC3G+2 more
ADARx Pharmaceuticals, Inc.45 enrolled25 locationsNCT06989359
Recruiting
Phase 2
A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy
IgA Nephropathy (IgAN)
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.30 enrolled1 locationNCT07305974
Recruiting
Phase 2
Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
IgA Nephropathy (IgAN)
Mayo Clinic16 enrolled2 locationsNCT06676579
Recruiting
Phase 2
Monthly Dosing of Atacicept in IgAN
IgA Nephropathy (IgAN)Berger Disease
Vera Therapeutics, Inc.90 enrolled1 locationNCT07020923
Recruiting
Phase 2
Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN
IgA Nephropathy (IgAN)
Haisco Pharmaceutical Group Co., Ltd.80 enrolled2 locationsNCT06670352